Stockscreener 앱 받기
131.18
0.74%
0.96
시장 영업 전:
131.18
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Neurocrine-Soleno deal garners Wall Street praise — analyst applauds business development acumen - MSN
Neurocrine reports sustained glucocorticoid reductions in CAH study By Investing.com - Investing.com South Africa
Neurocrine reports sustained dose reductions with CRENESSITY in CAH patients - StreetInsider
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia - ChartMill
NBIX Maintained by Leerink Partners -- Price Target Raised to $1 - GuruFocus
How Neurocrine Biosciences Inc. (NBIX) Affects Rotational Strategy Timing - Stock Traders Daily
Why this Bay Area company took a buyout offer that was nearly $2 billion less than an earlier bid - The Business Journals
3 Reasons Growth Investors Will Love Neurocrine (NBIX) - Yahoo Finance
Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $185 - Moomoo
Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a Bet - Zacks Investment Research
Lobbying Update: $940,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative
Neurocrine is making a $2.9 billion bet on a new kind of drug - MSN
Morgan Stanley Maintains Neurocrine Biosciences (NBIX) Overweight Recommendation - MSN
Neurocrine Biosciences (NASDAQ: SLNO) offers $53.00 per share cash to Soleno - Stock Titan
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Unveiling a 39.92% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Persistence Data And Options Activity - simplywall.st
A Look at Neurocrine Biosciences Inc (NBIX) After 3.8% Gain -- G - GuruFocus
Neurocrine's Acquisition Impacts Soleno Therapeutics (SLNO) Rati - GuruFocus
How New Real-World INGREZZA Data Versus AUSTEDO XR Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Hold at Zacks Research - MarketBeat
Sumitomo Mitsui Trust Group Inc. Decreases Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Massachusetts Financial Services Co. MA Sells 10,415 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Q3 2025 Earnings Preview - MSN
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with a Bullish Technical Setup - ChartMill
Neurocrine Expands CNS Pipeline With Nxera Schizophrenia Trial And Milestones - Sahm
How Investors May Respond To Neurocrine Biosciences (NBIX) INGREZZA Real-World Persistence Edge Over AUSTEDO XR - Yahoo Finance
Is It Time To Reassess Neurocrine Biosciences (NBIX) After Its Recent Share Price Pullback? - Yahoo Finance
Real World INGREZZA Data May Support Neurocrine’s Tardive Dyskinesia Lead - Sahm
Neurocrine Biosciences (NBIX) Stock Price, News & Analysis - MarketBeat
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
Neurocrine Biosciences | DEF 14A: Definitive information statements - Moomoo
Form DEFA14A NEUROCRINE BIOSCIENCES - StreetInsider
Neurocrine Biosciences (NBIX) seeks approval for 4M-share equity plan boost - Stock Titan
Is the Options Market Predicting a Spike in Neurocrine Biosciences Stock? - Zacks Investment Research
Neurocrine Biosciences identifies new CRF2 receptor agonists - BioWorld News
Robeco Institutional Asset Management B.V. Purchases 85,076 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking - MSN
Neurocrine Biosciences Inc (NBIX) Stock Up 3.6% and Still Undervalued -- GF Score: 96/100 - GuruFocus
Neurocrine Biosciences Inc (NBIX) Stock Up 3.6% and Still Underv - GuruFocus
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results - The AI Journal
Neurocrine to post Q1 results May 5, webcast starts at 4:30 ET - Stock Titan
Valbenazine Demonstrates Higher Persistence vs Deutetrabenazine in TD Patients - HMP Global Learning Network
INGREZZA shows higher treatment persistence than AUSTEDO XR in study - StreetInsider
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR - ChartMill
Soleno Therapeutics stock rallies 56.4% in a week: Here's why - MSN
Burney Co. Cuts Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN
FDA’s FIH plans. Plus: billion-dollar deals, funds — a BioCentury podcast - BioCentury
Investment Recap: Does Neurocrine Biosciences Inc have pricing power2026 Volume Leaders & Weekly High Return Stock Forecasts - baoquankhu1.vn
Technical Analysis: Can Neurocrine Biosciences Inc maintain its current growth rate2026 Dividend Review & Low Volatility Stock Suggestions - baoquankhu1.vn
Neurocrine Acquires Soleno for $2.9B - San Diego Business Journal
Portfolio Shifts: Is Neurocrine Biosciences Inc forming a double bottom2026 Momentum Check & Fast Gaining Stock Reports - baoquankhu1.vn
Nxera Pharma earns $22.5 million milestone haul from Neurocrine - Business Weekly
Nxera Pharma Co., Ltd. Initiates and Doses First Patient in Phase 2 Trial of Nbi-1117570 for Adults with Schizophrenia - marketscreener.com
3.13%
0.66%
자본화:
|
볼륨(24시간):